Birchview Capital, LP Apellis Pharmaceuticals, Inc. Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 14,000 shares of APLS stock, worth $468,440. This represents 0.37% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$468,440
Previous $537,000
24.95%
% of portfolio
0.37%
Previous 0.54%
Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
309Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$521 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$398 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$372 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$328 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$194 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.68B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...